LFST
LifeStance Health Group, Inc.
LFST's fundamentals are strong: revenue grew 23% and its operating margin rose 6 points to 6.2%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LFST Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
LFST's revenue, profitability, cash flow and balance sheet are all currently healthy.
LFST PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 54x | $14.15 | — |
| Current | 74x | $14.15 | — |
| Cheap | 95x | $17.99 | +27% |
| Fair | 128x | $24.39 | +72% |
| Expensive | 319x | $60.61 | +328% |
Historical ranges are pointers, not guarantees.
LFST's PE is 74x, but its earnings don't support one, so it isn't a reliable read right now.
LFST Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for LFST, with profitability improving. However, they disagree widely on these estimates.
LFST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.26 | +39% |
| Q3 2026 | $0.19 | +$0.21 |
| Q2 2026 | $0.13 | +$0.17 |
| Q1 2026 | $0.06 | +$0.15 |
| Q4 2025 | $0.02 | +$0.17 |
LFST has returned to profit: it earned $0.19 per share over the past year, after losing money the year before.
LFST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $455.9M | +25% |
| Q2 2026 | $435.4M | +26% |
| Q1 2026 | $403.5M | +21% |
| Q4 2025 | $382.2M | +17% |
| Q3 2025 | $363.8M | +16% |
| Q2 2025 | $345.3M | +11% |
| Q1 2025 | $333M | +11% |
| Q4 2024 | $325.5M | +16% |
LFST's revenue has grown year over year every quarter since early 2021: $456M last quarter, up 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.3% | +5.2 points |
| Q2 2026 | 7% | +7.9 points |
| Q1 2026 | 5.5% | +5 points |
| Q4 2025 | 4.7% | +4.4 points |
| Q3 2025 | 2% | +2 points |
| Q2 2025 | -0.8% | +4.3 points |
| Q1 2025 | 0.5% | +6.1 points |
| Q4 2024 | 0.3% | +12 points |
LFST's operating margin was 7.3% last quarter, up 5.2 points from the same quarter a year ago, near the top of its range since 2020.
LFST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $22.4M | +32% |
| Q2 2026 | $87.9M | +55% |
| Q1 2026 | $22.3M | +$32.6M |
| Q4 2025 | $46.6M | -17% |
| Q3 2025 | $17M | -3.8% |
| Q2 2025 | $56.6M | +45% |
| Q1 2025 | -$10.3M | +$16.7M |
| Q4 2024 | $56M | +941% |
LFST generated $179M in free cash flow over the past year, up 50% from the year before.
LFST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +3.9M shares |
| 1 year | +0.6% | +2.3M shares |
| 3 years | +4.7% | +17.6M shares |
LFST has 391M diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $24.8M |
| Q2 2026 | $48.5M |
| Q1 2026 | $49.1M |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LFST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 1.0x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 5.5x | High |
| Q4 2024 | 14.6x | High |
LFST's net debt is less than a year of its operating earnings (EBITDA), down from 1.6 years a year ago.
LFST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.6 | Overbought |
| Stochastic | 75.0 | Neutral |
LFST's weekly RSI is 72 (overbought) and its Stochastic is 75 (neutral).
LFST PE vs Healthcare Sector
| Metric | LFST | Sector median | Relative |
|---|---|---|---|
| PE | 74x | 26x | 188% above |
| PE % | 3 | 37 | 34 pts below |
LFST is trading at 74x earnings, a 188% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
LFST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.8 | 11% above |
| 20 week MA | $12.2 | 16% above |
| 50 week MA | $9.22 | 53% above |
| 100 week MA | $7.67 | 84% above |
| 200 week MA | $7.24 | 95% above |
LFST is in an uptrend: it's above all five of its weekly moving averages, and 95% above its 200-week average.
LFST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.0 | $10.1 | -58% |
| 2022 | $10.1 | $4.62 | -54% |
| 2023 | $4.62 | $7.83 | +69% |
| 2024 | $7.83 | $7.49 | -4.3% |
| 2025 | $7.49 | $7.13 | -4.8% |
| 2026 YTD | $7.13 | $14.2 | +98% |
LFST is up 98% so far in 2026, after finishing lower in four of the previous five years.